Key result
Nesiritide produces a prompt fall in systemic vascular resistance and pulmonary capillary wedge pressure, associated with rapid clinical improvement in decompensated heart failure.
Why the study?
Does nesiritide improve hemodynamics and clinical status in patients with acutely decompensated heart failure?
Does nesiritide improve hemodynamics and clinical status in patients with acutely decompensated heart failure?
Nesiritide is an effective parenteral therapy for acutely decompensated heart failure, improving hemodynamics and clinical symptoms.
Answers are grounded in this paper and cite their sources.
May support nesiritide for acute HF hemodynamics; leaves open outcome confirmation in randomized trials.
B-type natriuretic peptide, or nesiritide, recently gained US Food and Drug Administration approval as the first new parenteral agent approved for heart failure therapy in more than a decade. Nesiritide refers to a peptide identical to endogenous B-type natriuretic peptide, currently manufactured by recombinant DNA technology. Nesiritide has been evaluated in clinical trials involving more than 700 subjects. The drug produces a prompt fall in systemic vascular resistance and pulmonary capillary wedge pressure, associated with rapid clinical improvement in decompensated heart failure. Nesiritide represents an attractive choice for first-line therapy of acutely decompensated heart failure patients. In this review, the authors summarize the currently available data regarding the use of nesiritide, and offer recommendations for its use based on our experience with the compound in clinical trials.
No takes yet. Share an insight, caveat, or question.
Mills et al. (2002) conducted a review in Heart failure (n=700). Nesiritide was evaluated. Nesiritide produces a prompt fall in systemic vascular resistance and pulmonary capillary wedge pressure, associated with rapid clinical improvement in decompensated heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: